FDA approves Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread. Tabrecta is the first FDA-approved therapy to treat NSCLC with specific MET exon 14 skipping mutations.
from FDA Press Releases RSS Feed https://ift.tt/2L6DDHc
via IFTTT
No comments:
Post a Comment